

COMPANY PROFILE

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare.

COMPANY SNAPSHOT

Stock Symbol: ASXC

Stock Exchange: NYSE American

Headquarters: Research Triangle Park, NC

- Active sites in **13 countries across the US, EU, and Asia**
- **FDA, CE Mark, Roszdravnadzor, and PMDA approved**
- **>5,500 surgeries performed** to date
- **160+** global employees
- **>100** surgeon users

DIGITIZING MINIMALLY INVASIVE SURGERY (LAPAROSCOPY)

SENHANCE® SURGICAL SYSTEM

First and only Digital Laparoscopy surgical robotic platform globally.



SURGEON BENEFIT

- Enhanced control during surgery with surgeon eye-tracking camera control & 3DHD vision
- Enhanced precision through tremor filtrations and robotic stabilization
- Enhanced focus during surgery through optimized ergonomics and the sense of touch (haptics) for the first time in robotic surgery

AUGMENTED INTELLIGENCE

First surgical robotic system with Augmented Intelligence capabilities.



HOSPITAL BENEFIT

- Per-procedure cost similar to traditional laparoscopy
- Highly configurable, allowing hospitals to use existing operating room infrastructure

PATIENT BENEFIT

- Smallest instruments offered in robotics leading to >50% smaller incisions vs traditional robotic surgery

2021 STRATEGIC PRIORITIES

MARKET DEVELOPMENT

Building awareness & demonstrating clinical and economic value.

CLINICAL VALIDATION


Developing clinical evidence to support the value propositions of Senhance.

PORTFOLIO EXPANSION

Broadening the applicability of Senhance by adding new indications, features, and instruments.

MARKET OPPORTUNITY

The abdominal robotic surgery market currently has a very low penetration into the surgical market and is projected to grow at a **double digit CAGR over the foreseeable future.**¹



Senhance is well positioned for success in the unaddressed laparoscopic surgical market.

2021 HIGHLIGHTS

- 6 Senhance programs initiated - 5 in operating leases and one sale (1st installment in Russia)
- Over 1,500 surgeries performed in 2021 alone
- Well balanced use across multiple surgical specialty areas (general, gynecology, urology, colorectal, bariatric and pediatric)
- CE Mark for Intelligent Surgical Unit, enabling machine vision capabilities in Europe
- FDA 510(k) clearance for the expansion of machine vision capabilities on the Intelligent Surgical Unit
- FDA 510(k) clearance for articulating instruments

UPCOMING MILESTONES

- Initiate a total of 10-12 new Senhance programs for the year
- Publish additional health economic and clinical performance studies in peer reviewed journals

MANAGEMENT TEAM



AKIHISA AKAO
General Manager,
Japan K.K.



WOUTER DONDERS
General Manager,
EMEA / CIS



ANTHONY FERNANDO
President & CEO



SHAMEZE RAMPERTAB
Executive VP & CFO

FORWARD-LOOKING STATEMENT

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. The information contained herein is not a prospectus and does not constitute an offer to sell nor a solicitation of an offer to buy any security.

Learn more at [Asensus.com](https://www.asensus.com)